{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:10:54Z","timestamp":1784650254352,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1245\/s10434-020-08973-x","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T15:05:46Z","timestamp":1596553546000},"page":"1466-1480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive Patients"],"prefix":"10.1245","volume":"28","author":[{"given":"Phillip M.","family":"Kemp Bohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek T.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Chick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia O.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Travis","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Vreeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-819X","authenticated-orcid":false,"given":"Daniel W.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"issue":"2","key":"8973_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1634\/theoncologist.2009-0302","volume":"15","author":"AX Zhu","year":"2010","unstructured":"Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010;15(2):168\u201381.","journal-title":"Oncologist."},{"key":"8973_CR2","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109.","journal-title":"Clin Epidemiol."},{"issue":"3","key":"8973_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1470-2045(03)01021-0","volume":"4","author":"S Misra","year":"2003","unstructured":"Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167\u201376.","journal-title":"Lancet Oncol."},{"key":"8973_CR4","doi-asserted-by":"crossref","unstructured":"Levy AD, Murakata LA, Rohrmann CA, Jr. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics. 2001;21(2):295\u2013314; questionnaire, 549\u2013255.","DOI":"10.1148\/radiographics.21.2.g01mr16295"},{"issue":"3","key":"8973_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/01.sla.0000154118.07704.ef","volume":"241","author":"E Dixon","year":"2005","unstructured":"Dixon E, Vollmer CM, Jr., Sahajpal A, et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg. 2005;241(3):385\u201394.","journal-title":"Ann Surg."},{"key":"8973_CR6","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf. Published 2019. Updated 20 December 2019. Accessed 2020."},{"issue":"8","key":"8973_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/hpb.12444","volume":"17","author":"TA Aloia","year":"2015","unstructured":"Aloia TA, Jarufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015;17(8):681\u201390.","journal-title":"HPB (Oxford)."},{"issue":"22","key":"8973_CR8","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.3748\/wjg.v18.i22.2775","volume":"18","author":"Y Shirai","year":"2012","unstructured":"Shirai Y, Wakai T, Sakata J, Hatakeyama K. Regional lymphadenectomy for gallbladder cancer: rational extent, technical details, and patient outcomes. World J Gastroenterol. 2012;18(22):2775\u201383.","journal-title":"World J Gastroenterol."},{"issue":"5","key":"8973_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol."},{"issue":"3","key":"8973_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192\u2013202.","journal-title":"Br J Surg."},{"issue":"8","key":"8973_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658\u201367.","journal-title":"J Clin Oncol."},{"issue":"24","key":"8973_CR12","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617\u201322.","journal-title":"J Clin Oncol."},{"issue":"12","key":"8973_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015\u201327.","journal-title":"J Clin Oncol."},{"key":"8973_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijsu.2018.02.052","volume":"52","author":"JR Bergquist","year":"2018","unstructured":"Bergquist JR, Shah HN, Habermann EB, et al. Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study). Int J Surg. 2018;52:171\u20139.","journal-title":"Int J Surg."},{"issue":"3","key":"8973_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683\u201390.","journal-title":"Ann Surg Oncol."},{"issue":"14","key":"8973_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med."},{"issue":"30","key":"8973_CR17","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28(30):4581\u20136.","journal-title":"J Clin Oncol."},{"issue":"9","key":"8973_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.hpb.2017.05.010","volume":"19","author":"M Ghidini","year":"2017","unstructured":"Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB (Oxford). 2017;19(9):741\u20138.","journal-title":"HPB (Oxford)."},{"issue":"1","key":"8973_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12885-017-3967-0","volume":"18","author":"AR Siebenhuner","year":"2018","unstructured":"Siebenhuner AR, Seifert H, Bachmann H, et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer. 2018;18(1):72.","journal-title":"BMC Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08973-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08973-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08973-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T23:03:58Z","timestamp":1628031838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-08973-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["8973"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08973-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}